Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) reported that the European Medicines Agency has adopted a Positive Opinion to update the therapeutic indication for Soliris in the treatment of paroxysmal nocturnal haemoglobinuria (PNH) for patients with high disease activity regardless of history of transfusion. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) begun last trade with a price of $183.08 and throughout the trading session climbed at a high of $183.99. The day-trade ended with -1.50% to $180.37. The stock is going forward to its 52 week low with 32.27% and lagging behind from its 52 week high price with -11.28%. ALXN last month stock price volatility remained 3.56%.
- M. Castle & Co. (NYSE:CAS) declared that its financial results for the Q4 and year ended December 31, 2014. The firm consolidated net sales were $231.5M for Q4 2014 as compared to $233.2M in Q4 2013 and $245.5M in Q3 2014. The firm released a fourth quarter 2014 net loss of $39.1 million, or a net loss of $1.67 per diluted share. The firm released its Q4 2013 net loss was $12.6M, or a net loss of $0.54 per diluted share, and Q3 2014 net loss was $7.3 million, or a net loss of $0.31 per diluted share. A. M. Castle & Co. (NYSE:CAS) has the market capitalization of 75.9 Million. Shares of firm moved down -35.98% to close at $3.22 with the total traded volume of 2.56 Million. The firm has current ratio of 2.80 for the most recent quarter.
Concho Resources, Inc. (NYSE:CXO) reported that it has priced an upsized public offering of 6M shares of its common stock for total gross proceeds of $650M. The offering was upsized from the company’s initially plans to offer 5.6M shares. Concho Resources, Inc. (NYSE:CXO) stock price closed at $108.92 with the total traded volume of 5.36 Million shares. Its price to sales ratio ended at 4.56. Its market capitalization is 12.190 Billion. The stock owned by the Financial Institutions was 91.70% while by insiders was 1.40%.